US · Healthcare · Biotechnology
EPS came in at -0.23 against a street estimate of -0.25 — a beat of 8.0%.
Analysts rate Eupraxia Pharmaceuticals Inc. Common Stock a strong buy (12 buy, 0 hold, 0 sell out of 12) with an average price target of $16.35.
| Fund | Stake |
|---|---|
| Beutel, Goodman & Company Ltd. | 5.49% |
| Affinity Asset Advisors, LLC | 2.50% |
| Balyasny Asset Management LLC | 2.04% |
| Vivo Capital, LLC | 2.04% |
| Scotia Capital Inc | 2.03% |
| Partner Fund Management LP | 1.83% |
| Great Point Partners LLC | 1.82% |
| Jupiter Topco LLC | 1.58% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Eupraxia Pharmaceuticals Inc. Common Stock — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.